nodes	percent_of_prediction	percent_of_DWPC	metapath
Olmesartan—AGTR1—ACE Inhibitor Pathway—ACE—chronic obstructive pulmonary disease	0.00447	0.0718	CbGpPWpGaD
Olmesartan—Irbesartan—CYP1A2—chronic obstructive pulmonary disease	0.00369	0.271	CrCbGaD
Olmesartan—Losartan—ACE—chronic obstructive pulmonary disease	0.00335	0.246	CrCbGaD
Olmesartan—Valsartan—ALB—chronic obstructive pulmonary disease	0.00281	0.207	CrCbGaD
Olmesartan—SLCO1B3—Transport of organic anions—ALB—chronic obstructive pulmonary disease	0.00269	0.0432	CbGpPWpGaD
Olmesartan—Losartan—CYP1A2—chronic obstructive pulmonary disease	0.00238	0.175	CrCbGaD
Olmesartan—AGTR1—Arf6 signaling events—ADRB2—chronic obstructive pulmonary disease	0.00215	0.0344	CbGpPWpGaD
Olmesartan—AGTR1—ACE Inhibitor Pathway—NOS3—chronic obstructive pulmonary disease	0.00208	0.0334	CbGpPWpGaD
Olmesartan—SLCO1B3—Recycling of bile acids and salts—ALB—chronic obstructive pulmonary disease	0.00199	0.032	CbGpPWpGaD
Olmesartan—AGTR1—Peptide GPCRs—CXCR2—chronic obstructive pulmonary disease	0.00188	0.0302	CbGpPWpGaD
Olmesartan—SLCO1B1—Transport of organic anions—ALB—chronic obstructive pulmonary disease	0.00181	0.029	CbGpPWpGaD
Olmesartan—AGTR1—Arf6 trafficking events—ADRB2—chronic obstructive pulmonary disease	0.00169	0.0272	CbGpPWpGaD
Olmesartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.00158	0.0253	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—IL13—chronic obstructive pulmonary disease	0.00158	0.0253	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—IL17A—chronic obstructive pulmonary disease	0.00145	0.0233	CbGpPWpGaD
Olmesartan—AGTR1—ACE Inhibitor Pathway—TGFB1—chronic obstructive pulmonary disease	0.00138	0.0221	CbGpPWpGaD
Olmesartan—Losartan—ALB—chronic obstructive pulmonary disease	0.00137	0.101	CrCbGaD
Olmesartan—SLCO1B1—Recycling of bile acids and salts—ALB—chronic obstructive pulmonary disease	0.00134	0.0215	CbGpPWpGaD
Olmesartan—Cough—Arformoterol—chronic obstructive pulmonary disease	0.00122	0.00131	CcSEcCtD
Olmesartan—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.00121	0.00131	CcSEcCtD
Olmesartan—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.00121	0.0013	CcSEcCtD
Olmesartan—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.0012	0.0013	CcSEcCtD
Olmesartan—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.0012	0.0013	CcSEcCtD
Olmesartan—Cough—Montelukast—chronic obstructive pulmonary disease	0.00119	0.00129	CcSEcCtD
Olmesartan—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.00119	0.00128	CcSEcCtD
Olmesartan—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.00119	0.00128	CcSEcCtD
Olmesartan—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.00119	0.00128	CcSEcCtD
Olmesartan—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.00119	0.00128	CcSEcCtD
Olmesartan—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.00119	0.00128	CcSEcCtD
Olmesartan—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.00119	0.00128	CcSEcCtD
Olmesartan—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.00119	0.00128	CcSEcCtD
Olmesartan—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.00119	0.00128	CcSEcCtD
Olmesartan—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.00118	0.00128	CcSEcCtD
Olmesartan—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.00118	0.00128	CcSEcCtD
Olmesartan—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.00118	0.00128	CcSEcCtD
Olmesartan—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.00118	0.00128	CcSEcCtD
Olmesartan—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.00118	0.00128	CcSEcCtD
Olmesartan—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.00118	0.00128	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.00118	0.00127	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.00118	0.00127	CcSEcCtD
Olmesartan—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.00117	0.00127	CcSEcCtD
Olmesartan—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.00117	0.00127	CcSEcCtD
Olmesartan—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.00116	0.00126	CcSEcCtD
Olmesartan—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.00116	0.00126	CcSEcCtD
Olmesartan—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.00116	0.00126	CcSEcCtD
Olmesartan—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.00116	0.00125	CcSEcCtD
Olmesartan—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.00116	0.00125	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.00115	0.00125	CcSEcCtD
Olmesartan—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.00115	0.00125	CcSEcCtD
Olmesartan—Cough—Salbutamol—chronic obstructive pulmonary disease	0.00115	0.00124	CcSEcCtD
Olmesartan—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.00114	0.00123	CcSEcCtD
Olmesartan—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.00114	0.00123	CcSEcCtD
Olmesartan—Oedema—Formoterol—chronic obstructive pulmonary disease	0.00114	0.00123	CcSEcCtD
Olmesartan—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.00114	0.00123	CcSEcCtD
Olmesartan—Infection—Formoterol—chronic obstructive pulmonary disease	0.00113	0.00122	CcSEcCtD
Olmesartan—Infection—Arformoterol—chronic obstructive pulmonary disease	0.00113	0.00122	CcSEcCtD
Olmesartan—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.00112	0.00121	CcSEcCtD
Olmesartan—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.00112	0.00121	CcSEcCtD
Olmesartan—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.00112	0.00121	CcSEcCtD
Olmesartan—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.00112	0.00121	CcSEcCtD
Olmesartan—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.00112	0.00121	CcSEcCtD
Olmesartan—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.00111	0.00121	CcSEcCtD
Olmesartan—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.00111	0.00121	CcSEcCtD
Olmesartan—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.00111	0.0012	CcSEcCtD
Olmesartan—Oedema—Montelukast—chronic obstructive pulmonary disease	0.00111	0.0012	CcSEcCtD
Olmesartan—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.00111	0.0012	CcSEcCtD
Olmesartan—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.00111	0.0012	CcSEcCtD
Olmesartan—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.00111	0.0012	CcSEcCtD
Olmesartan—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.00111	0.0012	CcSEcCtD
Olmesartan—Infection—Montelukast—chronic obstructive pulmonary disease	0.00111	0.0012	CcSEcCtD
Olmesartan—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.0011	0.00119	CcSEcCtD
Olmesartan—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.0011	0.00119	CcSEcCtD
Olmesartan—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.00109	0.00118	CcSEcCtD
Olmesartan—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.00109	0.00118	CcSEcCtD
Olmesartan—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.00108	0.00117	CcSEcCtD
Olmesartan—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.00107	0.00116	CcSEcCtD
Olmesartan—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.00107	0.00116	CcSEcCtD
Olmesartan—Infection—Salbutamol—chronic obstructive pulmonary disease	0.00107	0.00115	CcSEcCtD
Olmesartan—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.00106	0.00115	CcSEcCtD
Olmesartan—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.00106	0.00115	CcSEcCtD
Olmesartan—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.00106	0.00115	CcSEcCtD
Olmesartan—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.00106	0.00114	CcSEcCtD
Olmesartan—Shock—Salbutamol—chronic obstructive pulmonary disease	0.00106	0.00114	CcSEcCtD
Olmesartan—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.00105	0.00114	CcSEcCtD
Olmesartan—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.00105	0.00113	CcSEcCtD
Olmesartan—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	0.00105	0.00113	CcSEcCtD
Olmesartan—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.00104	0.00113	CcSEcCtD
Olmesartan—SLCO1B3—Bile acid and bile salt metabolism—ALB—chronic obstructive pulmonary disease	0.00104	0.0167	CbGpPWpGaD
Olmesartan—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.00104	0.00112	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.00104	0.00112	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.00104	0.00112	CcSEcCtD
Olmesartan—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.00103	0.00111	CcSEcCtD
Olmesartan—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.00103	0.00111	CcSEcCtD
Olmesartan—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.00102	0.00111	CcSEcCtD
Olmesartan—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.00102	0.00111	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.00101	0.0011	CcSEcCtD
Olmesartan—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.00101	0.00109	CcSEcCtD
Olmesartan—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.001	0.00109	CcSEcCtD
Olmesartan—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.001	0.00108	CcSEcCtD
Olmesartan—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.001	0.00108	CcSEcCtD
Olmesartan—SLCO1B3—Transport of vitamins, nucleosides, and related molecules—ALB—chronic obstructive pulmonary disease	0.000998	0.016	CbGpPWpGaD
Olmesartan—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000996	0.00108	CcSEcCtD
Olmesartan—Injury—Prednisone—chronic obstructive pulmonary disease	0.00099	0.00107	CcSEcCtD
Olmesartan—AGTR1—Allograft Rejection—IL10—chronic obstructive pulmonary disease	0.000988	0.0159	CbGpPWpGaD
Olmesartan—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000987	0.00107	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000981	0.00106	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000981	0.00106	CcSEcCtD
Olmesartan—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.00098	0.00106	CcSEcCtD
Olmesartan—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.00098	0.00106	CcSEcCtD
Olmesartan—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.00098	0.00106	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000978	0.00106	CcSEcCtD
Olmesartan—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000972	0.00105	CcSEcCtD
Olmesartan—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000972	0.00105	CcSEcCtD
Olmesartan—Pain—Formoterol—chronic obstructive pulmonary disease	0.000972	0.00105	CcSEcCtD
Olmesartan—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000972	0.00105	CcSEcCtD
Olmesartan—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000971	0.00105	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000961	0.00104	CcSEcCtD
Olmesartan—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.00096	0.00104	CcSEcCtD
Olmesartan—Pain—Montelukast—chronic obstructive pulmonary disease	0.000952	0.00103	CcSEcCtD
Olmesartan—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000949	0.00103	CcSEcCtD
Olmesartan—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000945	0.00102	CcSEcCtD
Olmesartan—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000942	0.00102	CcSEcCtD
Olmesartan—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000941	0.00102	CcSEcCtD
Olmesartan—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000937	0.00101	CcSEcCtD
Olmesartan—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000937	0.00101	CcSEcCtD
Olmesartan—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000935	0.00101	CcSEcCtD
Olmesartan—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000933	0.00101	CcSEcCtD
Olmesartan—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000931	0.00101	CcSEcCtD
Olmesartan—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000929	0.00101	CcSEcCtD
Olmesartan—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000929	0.00101	CcSEcCtD
Olmesartan—Lethargy—Prednisone—chronic obstructive pulmonary disease	0.000929	0.001	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000926	0.001	CcSEcCtD
Olmesartan—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000925	0.001	CcSEcCtD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000924	0.0148	CbGpPWpGaD
Olmesartan—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000918	0.000993	CcSEcCtD
Olmesartan—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000918	0.000993	CcSEcCtD
Olmesartan—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.00091	0.000985	CcSEcCtD
Olmesartan—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000903	0.000977	CcSEcCtD
Olmesartan—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000903	0.000977	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—SOD3—chronic obstructive pulmonary disease	0.000898	0.0144	CbGpPWpGaD
Olmesartan—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000898	0.000972	CcSEcCtD
Olmesartan—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000898	0.000972	CcSEcCtD
Olmesartan—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000898	0.000972	CcSEcCtD
Olmesartan—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000898	0.000972	CcSEcCtD
Olmesartan—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000895	0.000969	CcSEcCtD
Olmesartan—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000888	0.000961	CcSEcCtD
Olmesartan—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000887	0.00096	CcSEcCtD
Olmesartan—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000887	0.00096	CcSEcCtD
Olmesartan—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000884	0.000957	CcSEcCtD
Olmesartan—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000884	0.000957	CcSEcCtD
Olmesartan—AGTR1—Peptide ligand-binding receptors—CXCR2—chronic obstructive pulmonary disease	0.000884	0.0142	CbGpPWpGaD
Olmesartan—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000882	0.000955	CcSEcCtD
Olmesartan—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.00088	0.000952	CcSEcCtD
Olmesartan—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.00088	0.000952	CcSEcCtD
Olmesartan—Face oedema—Prednisone—chronic obstructive pulmonary disease	0.000878	0.000951	CcSEcCtD
Olmesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—NOS3—chronic obstructive pulmonary disease	0.000878	0.0141	CbGpPWpGaD
Olmesartan—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000877	0.00095	CcSEcCtD
Olmesartan—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000852	0.000922	CcSEcCtD
Olmesartan—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000848	0.000918	CcSEcCtD
Olmesartan—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000848	0.000918	CcSEcCtD
Olmesartan—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000836	0.000905	CcSEcCtD
Olmesartan—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.000828	0.000896	CcSEcCtD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000824	0.0132	CbGpPWpGaD
Olmesartan—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000815	0.000882	CcSEcCtD
Olmesartan—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000815	0.000882	CcSEcCtD
Olmesartan—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000804	0.00087	CcSEcCtD
Olmesartan—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000804	0.00087	CcSEcCtD
Olmesartan—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000803	0.000868	CcSEcCtD
Olmesartan—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000799	0.000864	CcSEcCtD
Olmesartan—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000788	0.000852	CcSEcCtD
Olmesartan—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000778	0.000841	CcSEcCtD
Olmesartan—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000778	0.000841	CcSEcCtD
Olmesartan—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000774	0.000837	CcSEcCtD
Olmesartan—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	0.000771	0.000834	CcSEcCtD
Olmesartan—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.00077	0.000833	CcSEcCtD
Olmesartan—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000762	0.000824	CcSEcCtD
Olmesartan—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000759	0.000822	CcSEcCtD
Olmesartan—AGTR1—Arf6 signaling events—EGFR—chronic obstructive pulmonary disease	0.000757	0.0122	CbGpPWpGaD
Olmesartan—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000752	0.000813	CcSEcCtD
Olmesartan—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000752	0.000813	CcSEcCtD
Olmesartan—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000736	0.000797	CcSEcCtD
Olmesartan—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.000735	0.000796	CcSEcCtD
Olmesartan—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000734	0.000795	CcSEcCtD
Olmesartan—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000724	0.000784	CcSEcCtD
Olmesartan—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000723	0.000782	CcSEcCtD
Olmesartan—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000723	0.000782	CcSEcCtD
Olmesartan—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000717	0.000775	CcSEcCtD
Olmesartan—Rash—Formoterol—chronic obstructive pulmonary disease	0.000717	0.000775	CcSEcCtD
Olmesartan—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000716	0.000775	CcSEcCtD
Olmesartan—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000716	0.000775	CcSEcCtD
Olmesartan—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000712	0.00077	CcSEcCtD
Olmesartan—Headache—Formoterol—chronic obstructive pulmonary disease	0.000712	0.00077	CcSEcCtD
Olmesartan—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000711	0.000769	CcSEcCtD
Olmesartan—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.00071	0.000768	CcSEcCtD
Olmesartan—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000709	0.000768	CcSEcCtD
Olmesartan—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000708	0.000766	CcSEcCtD
Olmesartan—Rash—Montelukast—chronic obstructive pulmonary disease	0.000702	0.00076	CcSEcCtD
Olmesartan—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000701	0.000759	CcSEcCtD
Olmesartan—SLCO1B1—Bile acid and bile salt metabolism—ALB—chronic obstructive pulmonary disease	0.0007	0.0112	CbGpPWpGaD
Olmesartan—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.0007	0.000757	CcSEcCtD
Olmesartan—Headache—Montelukast—chronic obstructive pulmonary disease	0.000697	0.000755	CcSEcCtD
Olmesartan—AGTR1—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000692	0.0111	CbGpPWpGaD
Olmesartan—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000689	0.000746	CcSEcCtD
Olmesartan—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000682	0.000738	CcSEcCtD
Olmesartan—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.00068	0.000736	CcSEcCtD
Olmesartan—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000678	0.000733	CcSEcCtD
Olmesartan—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000677	0.000732	CcSEcCtD
Olmesartan—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000676	0.000732	CcSEcCtD
Olmesartan—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000676	0.000731	CcSEcCtD
Olmesartan—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000675	0.00073	CcSEcCtD
Olmesartan—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000675	0.00073	CcSEcCtD
Olmesartan—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000672	0.000727	CcSEcCtD
Olmesartan—SLCO1B1—Transport of vitamins, nucleosides, and related molecules—ALB—chronic obstructive pulmonary disease	0.00067	0.0108	CbGpPWpGaD
Olmesartan—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000663	0.000717	CcSEcCtD
Olmesartan—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000661	0.000716	CcSEcCtD
Olmesartan—ABCC2—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000661	0.0106	CbGpPWpGaD
Olmesartan—ABCC2—NRF2 pathway—SERPINA1—chronic obstructive pulmonary disease	0.00064	0.0103	CbGpPWpGaD
Olmesartan—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000637	0.00069	CcSEcCtD
Olmesartan—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000634	0.000686	CcSEcCtD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000621	0.00996	CbGpPWpGaD
Olmesartan—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000619	0.000669	CcSEcCtD
Olmesartan—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000615	0.000666	CcSEcCtD
Olmesartan—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000615	0.000666	CcSEcCtD
Olmesartan—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000606	0.000655	CcSEcCtD
Olmesartan—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000601	0.00065	CcSEcCtD
Olmesartan—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000595	0.000644	CcSEcCtD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000593	0.00951	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000589	0.00946	CbGpPWpGaD
Olmesartan—ABCC2—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	0.000586	0.0094	CbGpPWpGaD
Olmesartan—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000571	0.000618	CcSEcCtD
Olmesartan—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.000562	0.000609	CcSEcCtD
Olmesartan—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000557	0.000602	CcSEcCtD
Olmesartan—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.000556	0.000602	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	0.000555	0.00891	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000553	0.00888	CbGpPWpGaD
Olmesartan—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000552	0.000597	CcSEcCtD
Olmesartan—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000548	0.000593	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—SLC6A4—chronic obstructive pulmonary disease	0.000544	0.00874	CbGpPWpGaD
Olmesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—chronic obstructive pulmonary disease	0.000542	0.0087	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—CXCL8—chronic obstructive pulmonary disease	0.00054	0.00867	CbGpPWpGaD
Olmesartan—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000526	0.00057	CcSEcCtD
Olmesartan—AGTR1—Allograft Rejection—IL1B—chronic obstructive pulmonary disease	0.000518	0.00832	CbGpPWpGaD
Olmesartan—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000516	0.000559	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	0.000511	0.00819	CbGpPWpGaD
Olmesartan—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000508	0.00055	CcSEcCtD
Olmesartan—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000507	0.000549	CcSEcCtD
Olmesartan—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000507	0.000548	CcSEcCtD
Olmesartan—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000504	0.000545	CcSEcCtD
Olmesartan—AGTR1—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	0.000502	0.00805	CbGpPWpGaD
Olmesartan—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000501	0.000542	CcSEcCtD
Olmesartan—AGTR1—Peptide ligand-binding receptors—EDN1—chronic obstructive pulmonary disease	0.000495	0.00795	CbGpPWpGaD
Olmesartan—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000494	0.000535	CcSEcCtD
Olmesartan—Vertigo—Prednisone—chronic obstructive pulmonary disease	0.000492	0.000533	CcSEcCtD
Olmesartan—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000491	0.000532	CcSEcCtD
Olmesartan—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000489	0.000529	CcSEcCtD
Olmesartan—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000482	0.000521	CcSEcCtD
Olmesartan—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000467	0.000505	CcSEcCtD
Olmesartan—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000467	0.000505	CcSEcCtD
Olmesartan—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000465	0.000503	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000463	0.000501	CcSEcCtD
Olmesartan—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000461	0.000499	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000451	0.00724	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	0.000449	0.0072	CbGpPWpGaD
Olmesartan—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000447	0.000484	CcSEcCtD
Olmesartan—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000447	0.000484	CcSEcCtD
Olmesartan—Infection—Prednisone—chronic obstructive pulmonary disease	0.000444	0.000481	CcSEcCtD
Olmesartan—Shock—Prednisone—chronic obstructive pulmonary disease	0.00044	0.000476	CcSEcCtD
Olmesartan—AGTR1—G alpha (q) signalling events—HTR2A—chronic obstructive pulmonary disease	0.000439	0.00704	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—VEGFA—chronic obstructive pulmonary disease	0.000439	0.00704	CbGpPWpGaD
Olmesartan—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000439	0.000475	CcSEcCtD
Olmesartan—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000437	0.000472	CcSEcCtD
Olmesartan—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000434	0.00047	CcSEcCtD
Olmesartan—AGTR1—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000434	0.00696	CbGpPWpGaD
Olmesartan—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000432	0.000468	CcSEcCtD
Olmesartan—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000426	0.000461	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	0.000411	0.00659	CbGpPWpGaD
Olmesartan—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000407	0.000441	CcSEcCtD
Olmesartan—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000407	0.00044	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	0.000405	0.0065	CbGpPWpGaD
Olmesartan—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000405	0.000438	CcSEcCtD
Olmesartan—AGTR1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	0.000403	0.00646	CbGpPWpGaD
Olmesartan—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000394	0.000426	CcSEcCtD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	0.000393	0.0063	CbGpPWpGaD
Olmesartan—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000389	0.000421	CcSEcCtD
Olmesartan—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000388	0.00042	CcSEcCtD
Olmesartan—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000388	0.00042	CcSEcCtD
Olmesartan—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000386	0.000417	CcSEcCtD
Olmesartan—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000386	0.000417	CcSEcCtD
Olmesartan—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000382	0.000414	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	0.000377	0.00606	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	0.000376	0.00603	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000372	0.00597	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.00037	0.00593	CbGpPWpGaD
Olmesartan—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000369	0.000399	CcSEcCtD
Olmesartan—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000366	0.000396	CcSEcCtD
Olmesartan—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000366	0.000396	CcSEcCtD
Olmesartan—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000355	0.000384	CcSEcCtD
Olmesartan—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000354	0.000383	CcSEcCtD
Olmesartan—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000354	0.000383	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism—APIP—chronic obstructive pulmonary disease	0.000353	0.00566	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	0.000343	0.0055	CbGpPWpGaD
Olmesartan—AGTR1—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000339	0.00544	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000332	0.00533	CbGpPWpGaD
Olmesartan—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000321	0.000347	CcSEcCtD
Olmesartan—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000316	0.000342	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000316	0.00508	CbGpPWpGaD
Olmesartan—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000306	0.000331	CcSEcCtD
Olmesartan—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000296	0.00032	CcSEcCtD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000291	0.00466	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000287	0.00461	CbGpPWpGaD
Olmesartan—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000284	0.000308	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000283	0.00454	CbGpPWpGaD
Olmesartan—Rash—Prednisone—chronic obstructive pulmonary disease	0.000282	0.000305	CcSEcCtD
Olmesartan—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000282	0.000305	CcSEcCtD
Olmesartan—Headache—Prednisone—chronic obstructive pulmonary disease	0.00028	0.000303	CcSEcCtD
Olmesartan—AGTR1—Peptide ligand-binding receptors—CXCL8—chronic obstructive pulmonary disease	0.000268	0.0043	CbGpPWpGaD
Olmesartan—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000266	0.000287	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000255	0.00409	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000253	0.00406	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	0.000252	0.00404	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—APIP—chronic obstructive pulmonary disease	0.000237	0.0038	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.000234	0.00375	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	0.000232	0.00372	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000232	0.00372	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GC—chronic obstructive pulmonary disease	0.000227	0.00365	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000224	0.00359	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000221	0.00355	CbGpPWpGaD
Olmesartan—SLCO1B3—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	0.000214	0.00344	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.000211	0.00339	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	0.000181	0.00291	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	0.00018	0.00288	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	0.000177	0.00284	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.00017	0.00272	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	0.000169	0.00271	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	0.000168	0.0027	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	0.00016	0.00257	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.000157	0.00252	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	0.000156	0.0025	CbGpPWpGaD
Olmesartan—ABCC2—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	0.000154	0.00247	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GC—chronic obstructive pulmonary disease	0.000153	0.00245	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	0.000145	0.00233	CbGpPWpGaD
Olmesartan—SLCO1B1—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	0.000144	0.00231	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	0.000143	0.00229	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.000142	0.00228	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.000137	0.0022	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	0.000137	0.00219	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	0.000136	0.00219	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	0.00013	0.00208	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	0.00013	0.00208	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	0.000125	0.00201	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GSTT1—chronic obstructive pulmonary disease	0.000124	0.00199	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GCLC—chronic obstructive pulmonary disease	0.000123	0.00197	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	0.000122	0.00195	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	0.000114	0.00184	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	0.000114	0.00182	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	0.000113	0.00182	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CTGF—chronic obstructive pulmonary disease	0.000112	0.0018	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	0.000109	0.00175	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000103	0.00166	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	0.0001	0.00161	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—KL—chronic obstructive pulmonary disease	9.3e-05	0.00149	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.61e-05	0.00138	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	8.58e-05	0.00138	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.49e-05	0.00136	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.35e-05	0.00134	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GCLC—chronic obstructive pulmonary disease	8.25e-05	0.00132	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.91e-05	0.00127	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	7.79e-05	0.00125	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	7.73e-05	0.00124	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	7.69e-05	0.00123	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	7.67e-05	0.00123	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CTGF—chronic obstructive pulmonary disease	7.53e-05	0.00121	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.5e-05	0.0012	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	7.31e-05	0.00117	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	7.02e-05	0.00113	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	6.97e-05	0.00112	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.94e-05	0.00111	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	6.71e-05	0.00108	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	6.24e-05	0.001	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.78e-05	0.000928	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.7e-05	0.000916	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.32e-05	0.000853	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	5.13e-05	0.000823	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ALB—chronic obstructive pulmonary disease	5.1e-05	0.000818	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.04e-05	0.000809	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.89e-05	0.000786	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—NOS3—chronic obstructive pulmonary disease	4.88e-05	0.000783	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.67e-05	0.00075	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.15e-05	0.000665	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.94e-05	0.000633	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.75e-05	0.000602	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ALB—chronic obstructive pulmonary disease	3.43e-05	0.00055	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.37e-05	0.00054	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—NOS3—chronic obstructive pulmonary disease	3.28e-05	0.000526	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.09e-05	0.000496	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.03e-05	0.000486	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.54e-05	0.000408	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.33e-05	0.000374	CbGpPWpGaD
